Lv4
510 积分 2025-10-08 加入
Metabolic Dysfunction–Associated Steatotic Liver Disease
19天前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
19天前
已完结
Non-alcoholic fatty liver disease
1个月前
已完结
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
1个月前
已完结
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
2个月前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
2个月前
已完结
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
2个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
2个月前
已完结
Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
2个月前
已完结
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
2个月前
已完结
皖公网安备34019202002308
